Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methicillin Sodium

FDA-approved product (injectable, injection), marketed as Staphcillin.

Registered studies
50+
Lab records
29
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Methicillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF03

Repurposing investigation

Methicillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA10.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 8 of 26 lab records
  • E. coli: measured active in 0 of 2 lab records
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Methicillin Sodium in ChEMBL Registered studies below
Show the 29 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methicillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Gene Expression Analysis of Biofilm Formation and Antimicrobial Resistance in Clinical Methicillin-Resistant Staphylococcus Aureus

    NCT07796555 · start 2026-09-20

    Registered record
    Registry ID
    NCT07796555
    Conditions
    Staphylococcal Aureus Infection; Surgical Site Infection (SSI)
    Interventions
    swab from lesion; Biochemical reactions; Antibiotic sensitivity; Molecular detection of antibiotic resistance
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09-20
    Completion
    2027-11-02
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Aureus Infection; Surgical Site Infection (SSI)
    Interventionswab from lesion; Biochemical reactions; Antibiotic sensitivity; Molecular detection of antibiotic resistance
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

    NCT07376889 · start 2026-02-01

    Registered record
    Registry ID
    NCT07376889
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-01
    Enrolment
    2,096

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    PhasePhase 4
    Registry statusRecruiting

  • Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

    NCT06982105 · start 2025-05-20

    Registered record
    Registry ID
    NCT06982105
    Conditions
    Methicillin Resistant Staphylococcus Aureus; Osteomyelitis Acute; Septic Arthritis; Orbital Cellulitis; Facial Cellulitis; Mastoiditis; Cervical Adenitis; Retropharyngeal Abscess; Peritonsillar Abscess
    Interventions
    Trimethoprim Sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-20
    Completion
    2027-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin Resistant Staphylococcus Aureus; Osteomyelitis Acute; Septic Arthritis; Orbital Cellulitis +5 more
    InterventionTrimethoprim Sulfamethoxazole
    PhasePhase 4
    Registry statusRecruiting

  • Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection

    NCT06456424 · start 2024-11-20

    Registered record
    Registry ID
    NCT06456424
    Conditions
    Prosthetic Joint Infections of Hip; Staphylococcus Aureus Infection
    Interventions
    Phage therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2024-11-20
    Completion
    2025-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infections of Hip; Staphylococcus Aureus Infection
    InterventionPhage therapy
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement

    NCT06814223 · start 2024-10-28

    Registered record
    Registry ID
    NCT06814223
    Conditions
    Infection Catheter-Related
    Interventions
    • Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-28
    Completion
    2028-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Catheter-Related
    Intervention• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    PhasePhase 4
    Registry statusRecruiting

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Copper Use as Protection Against Antimicrobial Resistance in the ICU

    NCT04873557 · start 2020-11-02

    Registered record
    Registry ID
    NCT04873557
    Conditions
    Healthcare Associated Infection
    Interventions
    Copper-based surfaces plus copper-enriched linen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-11-02
    Completion
    2022-12-31
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthcare Associated Infection
    InterventionCopper-based surfaces plus copper-enriched linen
    PhaseNot applicable
    Registry statusCompleted

  • Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock

    NCT03683329 · start 2018-11-26

    Registered record
    Registry ID
    NCT03683329
    Conditions
    Critical Care; Cancer
    Interventions
    Antibiotic de-escalation; Standard treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-26
    Completion
    2024-07-26
    Enrolment
    398

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Care; Cancer
    InterventionAntibiotic de-escalation; Standard treatment
    PhasePhase 3
    Registry statusCompleted

  • Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

    NCT03012360 · start 2018-02-08

    Registered record
    Registry ID
    NCT03012360
    Conditions
    Mechanical Ventilation Complication; Critical Illness
    Interventions
    ceftriaxone; ciprofloxacin; imipenem; linezolid; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2024-07-07
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMechanical Ventilation Complication; Critical Illness
    Interventionceftriaxone; ciprofloxacin; imipenem; linezolid +1 more
    PhasePhase 4
    Registry statusTerminated

  • Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study

    NCT04097613 · start 2017-07-28

    Registered record
    Registry ID
    NCT04097613
    Conditions
    Chronic Rhinosinusitis (Diagnosis)
    Interventions
    Povidone-Iodine; Budesonide
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-07-28
    Completion
    2019-08-31
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis)
    InterventionPovidone-Iodine; Budesonide
    PhaseEarly phase 1
    Registry statusCompleted

  • Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making

    NCT03220386 · start 2017-05-01

    Registered record
    Registry ID
    NCT03220386
    Conditions
    Staphylococcus Aureus
    Interventions
    Decolonization by nasal Octinidin treatment and skin washings
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-05-01
    Completion
    2018-08-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus
    InterventionDecolonization by nasal Octinidin treatment and skin washings
    PhaseNot applicable
    Registry statusUnknown

  • Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

    NCT02814916 · start 2017-03-30

    Registered record
    Registry ID
    NCT02814916
    Conditions
    Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    Interventions
    Dalbavancin; Vancomycin; Oxacillin; Flucloxacillin; Cefadroxil; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-30
    Completion
    2024-01-01
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    InterventionDalbavancin; Vancomycin; Oxacillin; Flucloxacillin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Neonatal Vancomycin Trial

    NCT02790996 · start 2017-02-27

    Registered record
    Registry ID
    NCT02790996
    Conditions
    Late Onset Neonatal Sepsis
    Interventions
    Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-02-27
    Completion
    2020-04-01
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate Onset Neonatal Sepsis
    InterventionVancomycin
    PhasePhase 2
    Registry statusTerminated

  • Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study

    NCT02991131 · start 2016-12-17

    Registered record
    Registry ID
    NCT02991131
    Conditions
    Skin Disease, Infectious
    Interventions
    Tedizolid (Sivextro, BAY1192631); Linezolid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-12-17
    Completion
    2018-11-21
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Disease, Infectious
    InterventionTedizolid (Sivextro, BAY1192631); Linezolid
    PhaseNot recorded
    Registry statusTerminated

  • Staphylococcus Aureus Resistant to Methicillin (MRSA) Screening in Trauma

    NCT02842710 · start 2016-06-04

    Registered record
    Registry ID
    NCT02842710
    Conditions
    Emergencies
    Interventions
    GeneXpert®
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2016-06-04
    Completion
    2018-12-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergencies
    InterventionGeneXpert®
    PhaseNot applicable
    Registry statusWithdrawn